Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by BI Asset Management Fondsmaeglerselskab A S

Key Points

• BI Asset Management Fondsmaeglerselskab A S reduced its position in Teva Pharmaceutical Industries by 84.4%, holding 42,504 shares worth $653,000 after selling 230,130 shares in the first quarter.
• Multiple institutional investors significantly increased their stakes in Teva, with Harel Insurance Investments expanding by over 197,000%, now holding 22,055,547 shares valued at approximately $339 million.
• Teva Pharmaceutical Industries' stock has a consensus rating of "Buy" from analysts and a projected average target price of $24.71, reflecting positive sentiment in the market.

BI Asset Management Fondsmaeglerselskab A S decreased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 84.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,504 shares of the company's stock after selling 230,130 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Teva Pharmaceutical Industries were worth $653,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Ion Asset Management Ltd. raised its holdings in Teva Pharmaceutical Industries by 1.1% during the fourth quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company's stock worth $807,766,000 after purchasing an additional 409,778 shares in the last quarter. Menora Mivtachim Holdings LTD. increased its holdings in shares of Teva Pharmaceutical Industries by 2.8% in the 1st quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company's stock valued at $448,640,000 after acquiring an additional 808,074 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 1.2% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock valued at $404,775,000 after acquiring an additional 300,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock valued at $338,989,000 after acquiring an additional 22,044,407 shares during the period. Finally, Duquesne Family Office LLC increased its holdings in shares of Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock valued at $198,303,000 after acquiring an additional 7,569,450 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Buying and Selling

In related news, insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Placid Jover sold 6,053 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares in the company, valued at $102,693.84. This represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,001 shares of company stock worth $996,958 in the last three months. Corporate insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA traded down $0.08 during trading on Wednesday, hitting $18.08. 8,580,237 shares of the company were exchanged, compared to its average volume of 12,141,657. The company has a market cap of $20.73 billion, a price-to-earnings ratio of -112.97, a PEG ratio of 1.07 and a beta of 0.62. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The firm's fifty day moving average price is $16.79 and its 200 day moving average price is $16.29. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business's revenue was up .3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on TEVA. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective on the stock. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.